NEW YORK, July 22, 2026, 05:04 (EDT) – Danaher shares fell 11% after the company failed to meet expectations for biotech growth, triggering a reset in its valuation.
- Danaher stock ended the session at $179.01, dropping 10.99%. This marked the largest single-day decline for the company since June 2001.
- Quarterly revenue and adjusted earnings exceeded expectations, but full-year core growth guidance was narrowed to a range of 3%–4%.
- The guided adjusted earnings multiple dropped to 21.0 times from 23.8 times, calculated using the midpoints of the range.
U.S. cash markets were shut when this report was compiled. Danaher Corporation NYSE:DHR declined 11% in premarket trade on Wednesday after leading losses on the S&P 500 Tuesday.
The drop was a repricing of valuation, rather than a response to earnings. At Monday’s close, earlier guidance was priced at 23.8 times adjusted earnings. By Tuesday’s close, the higher forecast was trading at roughly 21 times.
| Reset metric | Before earnings | After earnings | Change |
|---|---|---|---|
| 2026 core-growth midpoint | 4.5% | 3.5% | -1.0 percentage point |
| Adjusted EPS midpoint | $8.45 | $8.525 | +0.9% |
| Danaher share price | $201.11 | $179.01 | -11.0% |
| Price/guided adjusted EPS | 23.8x | 21.0x | -2.8x |
Company guidance and closing prices are used to compute midpoints and multiples.
The midpoint for earnings edged up modestly. Meanwhile, the midpoint for core growth dropped around 22%. Investors focused much more on the latter figure.
An initial estimate based on the quarter’s diluted share total places the lost equity value at about $15.6 billion, which is approximately 1.6 times greater than Masimo’s $9.9 billion purchase price. However, Chief Financial Officer Matt Gugino noted that just over $100 million in bioprocessing revenue moved into 2027.
The response points to a wider anxiety. Investors seem to be doubting the sustainability of growth and reliability of forecasts, rather than just the timing of shipments.
The quarter outperformed forecasts. Revenue rose 5.5% to $6.27 billion, surpassing the FactSet consensus of $6.11 billion. Adjusted earnings came in at $1.94 per share, above the anticipated $1.84. Core revenue advanced 3%, higher than the 0.5% growth seen in the prior quarter.
The decline was centered in biotechnology. Segment core sales increased by 2.5%, falling approximately 300 basis points short of Wall Street expectations. Life Sciences advanced 5.5%. Diagnostics rose 2%, or 5% excluding respiratory testing.
Chief Executive Rainer Blair stated, “Underlying order trends remained strong and bioprocessing orders grew mid-teens in the quarter.” As a result, orders significantly outpaced the reported growth in biotechnology. Danaher Corporation Investors
Analysts maintained a cautious outlook. Matt Larew, an analyst at William Blair, described bioprocessing as “surprisingly soft.” Subbu Nambi of Guggenheim said the focus would remain on biotechnology growth in the second half. Investor’s Business Daily
Danaher projects third-quarter core growth between 2% and 3%, factoring in a 2.5-point drag from respiratory testing. Growth, if respiratory testing is excluded, is expected to near 5%, and biotechnology is forecast to recover to mid-single-digit growth.
The company maintains its outlook for total core growth in the mid-single digits for the fourth quarter. That projection is now seen as more significant. Investors are looking for confirmation that robust order volumes will translate into actual shipments.
Danaher increased its adjusted EPS outlook to a range of $8.45–$8.60, up from the previous $8.35–$8.55. The earlier completion of Masimo’s acquisition contributed to the move. Free cash flow climbed 15.5% to $1.27 billion for the quarter.
The stock finished at $205.01 last Thursday before dropping 12.7% by Tuesday. On Tuesday, the S&P 500 rose 0.9%, underscoring that Danaher’s decline was mostly tied to company issues.
The upcoming industry test is set for Thursday. Thermo Fisher Scientific NYSE:TMO will release its results prior to the market opening on July 23. The company’s insights on biopharma and research demand will indicate if Danaher’s recent softness is seen elsewhere in the sector.
Risks: There is potential for further delays in bioprocessing shipments. Fluctuations in respiratory demand could persist. The integration of Masimo, acquisition-related debt, and tariffs present additional execution and liquidity challenges.
Danaher trades at 21 times guided adjusted earnings, making it less expensive than Monday. However, the lower valuation multiple demands validation. Orders in the mid-teens need to translate to biotechnology sales in the mid-single digits.
Related articles: NYSE:DHR
